Hospira Q3 net income up
The company has reported net sales of $925.5 million for the third quarter of 2008, an increase of 10.4%, compared to $838 million posted in the third quarter
Ionis Pharmaceuticals has entered a licence agreement granting global pharmaceutical company Recordati exclusive rights to develop and commercialise zilganersen to treat Alexander disease (AxD) in countries outside the US.